California
Biotech Insights

Biotech Market Update

Khartis emerges from stealth with $95M, Skye combines with Redx to form Fibrx

August 18, 2026

Recent Funding: Epicrispr Biotechnologies (SF) Secures $90M Series C After Early FSHD Data The Series C brought in $90 million on the back of promising early clinical data for EPI-321, an epigenetic gene-silencing candidate for facioscapulohumeral muscular dystrophy (FSHD), under CEO Amber Salzman. The raise deepens the company’s bet on epigenetic editing — modifying gene […]

Biotech Leader Spotlight

Ben Buelow, CEO & Co-Founder of 92Bio

August 13, 2026

Ben Buelow is CEO and Co-Founder of 92Bio. Ben and the 92Bio team are bringing their industry leading expertise in therapeutic antibody discovery and development to create the next generation of multi-specific antibodies for the treatment of cancer. He previously served as CEO of Ancora Biotech (2022-2024) and Chief Medical Officer of Teneobio from 2016-2021, when it was acquired by Amgen. He has guided five antibodies from concept to clinic since 2016, with two now in phase 3 registrational trials. He has published ~25 peer-reviewed papers and has presented at numerous national and international scientific conferences. Ben completed his residency and surgical pathology fellowship as chief resident at UCSF in 2016. He received an MD with honors and a PhD in Immunology from the University of Washington in 2011.

Biotech Market Update

Expedition closes $115M Series B, aTyr cuts 60% of staff, Jazz to acquire Actio for $820M

August 11, 2026

Recent Funding: Expedition Therapeutics (SF) Closes $115M Series B for COPD Drug The oversubscribed round was led by General Atlantic with backing from Sanofi, funding the push of oral DPP1 inhibitor EXPD-101 into Phase 2 for chronic obstructive pulmonary disease. The company dosed the first patient in that Phase 2 trial alongside the raise, following […]

Biotech Market Update

Genentech cuts 103 jobs, Processa acquires Vidya, Braveheart sets terms for $275M IPO

August 4, 2026

Recent Layoffs: Genentech (SF) to Cut 103 Jobs at South San Francisco Headquarters The Roche subsidiary filed a WARN notice for cuts effective July 29 across several business functions, not just the previously-disclosed Research and Early Development (gRED) reorganization. This is Genentech’s latest round in a rough year, bringing its total California layoffs to nearly […]

Biotech Market Update

Crystalys raises $130M Series B, Scribe prices upsized $129M IPO

July 28, 2026

Recent Funding: Crystalys Therapeutics (SD) Raises Oversubscribed $130M Series B for De-Risked Gout Therapy The round, led by Frazier Life Sciences, Wellington Management, HBM Healthcare Investments, Soleus Capital, Cormorant Asset Management and others, brings Crystalys’s total raised to $335M. Proceeds advance dotinurad, a once-daily oral URAT1 inhibitor for gout, through global Phase 3 development and […]

Biotech Market Update

Chai raises $400M Series C, Jasper merges with Kira, Attovia files for IPO

July 21, 2026

Recent Funding: Chai Discovery (SF) Raises $400M Series C, Tripling Its Valuation in Seven Months The AI-driven molecular design startup closed a Series C led by Index Ventures, Kleiner Perkins, and Sequoia Capital at a $3.8B valuation, with its models already licensed by Eli Lilly, Pfizer, and Novartis. M&A, Deals, Partnerships: Jasper Therapeutics (SF) Merges […]

California Biotech Insights

California
Biotech Insights